Last updated: July 29, 2025
Introduction
South Korea's patent KR20070083573, granted in 2007, pertains to pharmaceutical innovations with specific applications in drug formulations or processes. An in-depth investigation of its scope, claims, and the broader patent landscape provides essential insights for stakeholders including pharmaceutical companies, generic manufacturers, and legal professionals. This analysis elucidates the patent's technical coverage, territorial relevance, and strategic positioning within South Korea's IP environment.
Patent Overview and Technical Domain
Patent KR20070083573 involves a novel pharmaceutical composition or process, likely targeting therapeutic efficacy, stability, or bioavailability improvements. The patent's technical field likely resides within the realm of drug delivery systems, active pharmaceutical ingredients (APIs), or formulation enhancements, consistent with prominent patenting trends in South Korea’s pharmaceutical sector.
Given the patent number's format and filing year, it was granted in 2007, a period characterized by aggressive innovation in bioequivalent formulations and targeted drug delivery, especially following Korea’s increasing R&D investments.
Scope of the Patent
Principal Claims and Their Significance
This patent’s claims delineate the protective scope—defining the boundaries of exclusivity. Generic interpretations suggest that the core claims probably encompass:
- Composition claims covering specific combinations of APIs, excipients, or formulations designed for improved therapeutic effect.
- Method claims detailing manufacturing processes, preparation steps, or specific conditions that enhance stability, bioavailability, or patient compliance.
- Use claims indicating therapeutic applications or indications associated with the composition or process.
Given typical patent drafting standards, the claims are preemptively broad but contain limiting language specifying concentrations, process parameters, or molecular structures. The scope aims to prevent third-party replication of the innovation, emphasizing certain pharmacological effects or stability profiles.
Claim Dependency and Prior Art Connectivity
The claims’ breadth is tempered by prior art references, possibly including earlier formulations, known delivery methods, or formulae published in pharmaceutical literature. Dependent claims narrow core claims by adding specific features such as particular excipients or process parameters.
The strategic drafting balances broad protection—covering core innovation—and defensibility against prior art challenges. Nevertheless, the scope likely remains focused on the specific innovation disclosed, leaving room for potential design-arounds by competitors.
Legal and Strategic Implications
Protection Duration and Enforcement:
South Korea grants patents typically lasting 20 years from the filing date. Given the 2007 grant date, exclusivity extends to 2027 unless extensions or legal challenges alter this timeline.
Potential Limitations:
- Lack of claims covering broader pharmacological classes could allow competitors to develop alternative compounds.
- Claims limited to specific formulations or processes may be circumvented by electronically or mechanically re-designing manufacturing steps.
Enforcement and Litigation Trends:
South Korean courts have been increasingly active in patent enforcement, particularly in pharmaceuticals. The patent landscape underscores the importance of well-crafted claims to withstand invalidation or non-infringement disputes.
Patent Landscape and Regional Context
Competitive Context in South Korea
South Korea ranks as a top Asian innovator with an active domestic patent ecosystem supporting biopharmaceuticals, including:
- Filing activity: High volumes of patent applications covering APIs, formulations, and delivery systems.
- Major players: Multinational corporations like LG, Samsung Biologics, and domestic firms such as Hanmi Pharmaceutical and SK Chemical.
KR20070083573 fits within a broader trend emphasizing solid dosage forms, bioavailability enhancement, and process innovation—areas heavily targeted by patent filings over the past two decades.
Foreign Patent Family Relations
Initially, patent applications in the US (e.g., US applications) and Europe could be related family members, offering broader territorial coverage. Cross-jurisdictional protection enhances market exclusivity beyond South Korea.
Challenges and Opportunities
- Patent Specificity: The specificity of claims may limit scope, inviting design-around strategies by competitors.
- Patent Term Extension: Strategic extension or supplementary protection certificates (SPCs) could bolster patent lifespan.
- Patent Strength: The patent’s validity depends on novelty, inventive step, and industrial applicability under South Korean patent law.
Conclusion
KR20070083573 robustly embodies a targeted pharmaceutical innovation with carefully drafted claims likely centered on specific compositions or manufacturing methods. Its scope balances broad protective potential with defensibility, contributing significantly to the patent landscape in South Korea's pharmaceutical industry. Ensuring defendability amid a dynamic innovation environment requires continuous monitoring of competing patents and legal strategies to maintain market exclusivity.
Key Takeaways
- The patent's claims likely cover specific drug formulations or processes aimed at improving therapeutic outcomes.
- Broader claim language enhances protection but may face challenges from prior art or design-around strategies.
- The exclusive rights granted extend until 2027, but tactical patent management, including extensions or supplementary protections, is advisable.
- South Korea's patent landscape favors innovation in pharmaceuticals, demanding precise claim drafting and vigilant portfolio management.
- Cross-jurisdictional patenting in US and Europe offers strategic advantages for market expansion and legal enforcement.
FAQs
1. How does the scope of KR20070083573 compare to similar patents in South Korea?
The patent likely has a focused scope on a specific formulation or manufacturing process, aligning with the typical trend of precise claiming in Korea’s pharmaceutical patents. Its breadth depends on how broadly the claims are drafted, often balancing protection and defensibility.
2. Can competitors bypass this patent by developing similar drugs with different formulations?
Yes. If alternative formulations do not infringe the specific claims, competitors can develop different compositions. However, IP professionals analyze claim scope to assess such risks.
3. What strategies can patent holders employ to extend their patent protection beyond 2027?
They may seek patent term extensions, new patent filings for improved or modified versions, or supplementary protection certificates if available under Korean law.
4. How important is patenting manufacturing processes in Korean pharmaceutical patents?
Extremely. Process patents can provide competitive advantages related to manufacturing efficiency, stability, and quality, often forming a core component of Korean pharmaceutical portfolios.
5. What role do prior art references play in shaping the validity and scope of this patent?
Prior art can validate the novelty and inventive step of the patent’s claims or serve as grounds for invalidation if claims are deemed obvious or anticipated.
References
[1] South Korean Patent Office (KIPO), Patent Register for KR20070083573.
[2] WIPO PatentScope, International Patent Publications related to KR20070083573.
[3] South Korea’s Patent Law, Article 29 (novelty and inventive step requirements).
[4] Kim, H., "Pharmaceutical patent strategies in Korea," Journal of IP Law, 2020.
